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We also agree that further studies with
an intravenous form of sildenafil, which is
currently not available in our country,
should be performed, especially with re-
gard to the period of weaning from cardio-
pulmonary bypass, and we hope that our
study will draw much attention and further
clinical research in this area.
Jae Kwang Shim, MD
Yong Seon Choi, MD
Young Lan Kwak, MD
Department of Anesthesiology and Pain Medicine
Anesthesia and Pain Research
Seoul, South Korea
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Redo mitral valve repair
To the Editor:
We read with interest the recent article of
Suri and colleagues1 in the Journal. The
authors reported their 35-year experience
of redo surgery for mitral valve (MV) re-
pair failure in degenerative disease. They
concluded that MV re-repair should be per-
formed whenever technically feasible ow-
ing to the improved survival and better left
ventricular performance allowed by the
procedure in comparison to MV replace-
ment. Although our surgical management
of such patients is similar, we found some
concerns with their reported data that need
clarification.
Most patients were operated on between
1980 and 2000. Regarding the survival
curve (Figure 1 from their article), only
25% of patients from both groups (repair
and replacement) were still at risk at 5
years. Because mortality within that time
frame was certainly not 75%, that means
that many patients were lost to follow-up.
This raises questions about the accuracy of
the survival comparisons between the two
groups. On the other hand, it would have
been interesting to have the actuarial sur-
vivals at 10, 15, and 20 years inasmuch as
the study extends over a period of 35 years.
There is some inconsistency with the
results of multivariate analysis of the pre-
dictors of late survival. According to the
authors, “late” survival was better after MV
re-repair. Survival was also better when the
indication for reoperation was recurrent
mitral regurgitation. However, this later
group of patients (with regurgitation) un-
derwent predominantly MV replacement.
Do the authors have an explanation for
these contradictory results?
It would have been interesting to have
some echocardiographic data regarding the
MV function when reading the results of a
(long-term) MV repair study.
Six patients from the re-repair group
underwent a third operation during their
follow-up. Unfortunately, the intraopera-
tive anatomic findings were not reported.
In our experience, failure of re-repair is
usually related to retraction of the posterior
leaflet (type IIIa). This lesion is easily cor-
rected by pericardial patch extension of the
posterior leaflet, even in a third operation.2
Most important, we believe that surgeons
should carefully inspect the posterior leaf-
let for any retraction before performing re-
repair for primary MV repair failure. Even
when failure is due to an anterior leaflet
prolapse, surgeons should not hesitate to
extend the posterior leaflet when it appears
retracted, even moderately. We believe that
is a simple way to improve the long-term
results of MV re-repair.
Finally, our surgical experience in MV
repair failure in degenerative disease is in
favor of re-repair. We therefore agree with
the conclusion from the Mayo Clinic study,
but we do have some concerns regarding
the way it was presented.
Rachid Zegdi, MD, PhD
Paul Achouh, MD
Jean-Noël Fabiani, MD
Université René Descartes—Paris V
Department of Cardiovascular Surgery
Hôpital Européen Georges Pompidou
Paris, France
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Reply to the Editor:
We thank Drs Zegdi, Achouh, and Fabiani
for their comments and are happy to pro-
vide the requested clarifications.
Regarding the issue of patients at risk in
the survival analysis, mean follow-up was
3.3 years, and 73% of patients alive at
follow-up had this information available
within 5 years of the date of review. Ques-
tionnaires were sent to all patients; how-
ever, current US Health Insurance Portabil-
ity and Accountability Act (HIPAA) laws
prohibit telephone inquiries to those who
do not respond to mailed surveys. We also
tracked vital statistics through the Social
Security Death Index and have no reason to
suspect that we missed a high number of
deaths. We believe that the remaining pa-
tients were lost to follow-up at random.
Of 145 patients undergoing reoperation
for recurrent mitral regurgitation alone, 64
(44%) had re-repair and 81 (56%) had re-
placement. The concern in the letter to the
Editor as to whether recurrent mitral regur-
gitation and mitral re-repair are “contradic-
tory” predictors of improved long-term sur-
vival is somewhat perplexing. Multivariate
analyses attempt to control for confounding
interrelated variables and identify indepen-
dent predictors of end points such as sur-
vival, which is impossible to accomplish
from a simple comparison of univariately
significant factors alone.
The echocardiographic follow-up of
these patients is an area of ongoing inves-
tigation by our group and is currently being
analyzed in other clinical studies. In our
practice, the recurrence of moderate-to-se-
vere mitral regurgitation or significant ste-
nosis usually leads to surgical assessment
and intervention.
All patients in our study had primary
mitral regurgitation owing to purely degen-
erative mitral valve disease. Leaflet retrac-
tion is usually rare unless ischemic or inflam-
matory components coexist. Additionally, we
do not generally perform quadrangular resec-
tions and sliding repairs, which may explain
the frequency with which Dr Zegdi’s group
reports mitral leaflet retraction at reoperation.
The 6 patients who required a second re-
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operation had failure of the re-repair result-
ing from recurrent mitral regurgitation in 5
and hemolysis in 1.
We are grateful to the Editor for the
opportunity to further clarify these points.
Rakesh M. Suri, MD, DPhil
Hartzell V. Schaff, MD
Cardiovascular Surgery
Mayo Clinic College of Medicine
Rochester, Minn
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Limitations with aprotinin in thoracic
aortic surgery: Understanding the
clinical outcome beyond bleeding
To the Editor:
I read with great interest the recent article
by Dr Sedrakyan and colleagues1 detailing
their experience with aprotinin in thoracic
aortic surgery, using a retrospective case-
control matching analysis (n  168 [1995-
2003]: deep hypothermic circulatory arrest
(DHCA) 64.3%–67.9%). The authors con-
clude in their article that there is American
Heart Association level II evidence for
aprotinin in thoracic aortic surgery.
I have the following questions for the
authors of this excellent study:
1. What was the reexploration rate for
bleeding in this case-control series?
Did antifibrinolytic exposure make
any difference? This outcome vari-
able is an important determinant of
mortality after thoracic aortic sur-
gery.2 It would be useful to know
whether aprotinin was associated
with a lower take-back rate.
2. Were anesthetic technique and an-
esthetic drug doses equivalent in
both groups? This is an important
determinant of postoperative venti-
lation time. Was this potential con-
founder considered before conclud-
ing that aprotinin is associated with
a decrease in total ventilation time?
3. Were the clinical outcomes, includ-
ing renal failure and dysfunction,
equivalent in the subgroup with
DHCA? Our group has recently re-
ported that aprotinin may be associ-
ated with renal dysfunction after
DHCA.3 Does a mixed thoracic aor-
tic cohort explain the differences in
these studies?
4. Were there criteria for antifibrino-
lytic choice in this cohort (eg, pre-
vious aprotinin exposure; level of
renal impairment)? When was the
aprotinin administered (eg, before
skin incision or after dissection
and cannulation for cardiopulmo-
nary bypass)? It would be useful to
understand the dosing style of apro-
tinin in this study.
5. Were there any hypersensitivity re-
actions to aprotinin?4 Were there
any cases of unexpected vascular
thrombosis?5
I look forward to input from the authors.
Again, I congratulate them for a most valu-
able article on this challenging topic.
John G. T. Augoustides, MD, FASE
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA
References
1. Sedrakyan A, Wu A, Sedrakyan G, Diener-
West M, Tranquilli M, Elefteriades J. Apro-
tinin use in thoracic aortic surgery: safety and
outcomes. J Thorac Cardiovasc Surg. 2006;
132:909-17.
2. Augoustides JG, Pochettino A, McGarvey
ML, Cowie D, Weiner J, Gambone AJ, et al.
Clinical predictors for mortality in adults un-
dergoing thoracic aortic surgery requiring
deep hypothermic circulatory arrest. Ann
Card Anaesth. 2006;9:114-9.
3. Augoustides JG, Pochettino A, Ochroch EA,
Cowie D, Weiner J, Gambone AJ, et al. Renal
dysfunction after thoracic aortic surgery re-
quiring deep hypothermic circulatory arrest:
definition, incidence, and clinical predictors.
J Cardiothorac Vasc Anesth. 2006;20:673-7.
4. Beierlein W, Scheule AM, Dietrich W, Zi-
emer G. Forty years of clinical aprotinin use:
a review of 124 hypersensitivity reactions
Ann Thorac Surg. 2005;79:741-8.
5. Augoustides JG, Lin J, Gambone AJ, Cheung
AT. Fatal thrombosis in an adult after thora-
coabdominal aneurysm repair with aprotinin
and deep hypothermic circulatory arrest. An-
esthesiology. 2005;103:215-6.
doi:10.1016/j.jtcvs.2006.11.071
Reply to the Editor:
We appreciate Dr Augoustides’ kind com-
ments regarding our article.1 We are very
much aware of the important contributions
he and his colleagues have made on the
topic at hand.
We provide the following specific re-
sponses to the insightful comments and
questions raised in Dr. Augoustides’ letter.
1. Three patients required reexplora-
tion for bleeding—1 in the aprotinin
group and 2 in the control group.
2. Anesthesia was by a balanced nar-
cotic/inhalation technique in both
groups.
3. Renal failure occurred in 3 patients
in the control group and 2 in the
aprotinin group.
4. Aprotinin was administered after
the skin incision. It is our policy to
avoid aprotinin in the rare circum-
stance of recent prior aprotinin ex-
posure.
5. There were no clinically appreciated
hypersensitivity reactions to aproti-
nin. There were no cases of unex-
pected vascular thrombosis.
In sum, the points raised by Dr Augous-
tides are all very cogent. On each point,




John A. Elefteriades, MD
Department of Cardiothoracic Surgery
Yale University School of Medicine,
New Haven, CT
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Unilateral as well as bilateral
infiltrates should remain part of the
definition of pulmonary graft
dysfunction
To the Editor:
We read with interest the article by Oto and
associates1 in the December 2006 issue of
the Journal. The authors underestimate the
importance of unilateral infiltrates. We dis-
agree with the statement, “only bilateral
infiltrates should be used as part of the
definition of primary graft dysfunction” de-
spite their convincing statistical methods.
We explain why.
The guidelines of pulmonary graft dys-
function (PGD)2 and validation3 thereof is
for the clinician to make sense of the data
and standardize reporting. The emphasis by
the consensus committee on PGD was on
providing a definition that could also help
in management and prognosis.2 PGD is a
biological process of reperfusion–ischemic
injury redefined with respect to alveolar–
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